摘要
目的 探究人参多糖注射液联合信迪利单抗对晚期非小细胞肺癌(NSCLC)化疗患者的作用。方法 选取南阳张仲景医院2020年2月至2022年2月收治的106例NSCLC患者,随机分为两组,各53例。两组均接受TP化疗方案,对照组在此基础上接受信迪利单抗,观察组在对照组基础上接受人参多糖注射液。比较两组生活质量改善率、不良事件发生情况、疗效,比较两组治疗前后血清肿瘤标志物[癌胚抗原(CEA)、血管内皮生长因子(VEGF)、神经元特异性烯醇化酶(NSE)、糖类抗原19-9(CA19-9)]、调节性T细胞(Treg)/辅助性T细胞(Th17)、程序性死亡受体1(PD-1)/PD-1配体(PD-L1)信号通路相关指标水平,随访1 a,统计对比两组生存情况。结果 观察组客观缓解率、疾病控制率均较对照组高(P<0.05);观察组胃肠道反应、白细胞降低及血红蛋白降低发生率均较对照组低(P<0.05);观察组生活质量改善率(56.60%)高于对照组(30.19%)(P<0.05);两组治疗1、3个周期后血清CEA、VEGF、CA19-9、NSE、Treg细胞、Th17细胞、Treg/Th17、PD-1、PD-L1水平较治疗前下降(P<0.05),且观察组较对照组低(P<0.05);两组1 a生存率比较差异无统计学意义(P>0.05)。结论 人参多糖注射液联合信迪利单抗治疗晚期NSCLC化疗患者,可增强机体免疫力,发挥增效减毒作用,提高患者生存质量。
Objective To investigate the effect of ginseng polysaccharide injection combined with sindillizumab in patients with advanced non-small cell lung cancer(NSCLC)treated with chemotherapy.Methods A total of 106 patients with NSCLC from Nanyang Zhang Zhongjing Hospital from February 2020 to February 2022 were collected and randomly divided into two groups,with 53 patients in each group.Both groups were given TP chemotherapy regimen,on this basis,the control group was given sindilizumab,on the basis of the control group,the observation group was given ginseng polysaccharide injection.The improvement rate of quality of life,adverse events,and efficacy between the two groups was compared.The serum tumor markers[carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF),neuronal specific enolase(NSE),carbohydrate antigen 19-9(CA19-9)],T regulatory cell(Treg)/T helper cell 17(Th17),and programmed death-1(PD-1)/PD-1 ligand(PD-L1)signaling pathway related indicators before and after treatment between the two groups were compared.After one year follow-up,the survival status of the two groups were compared.Results The objective response rate and disease control rate of observation group were higher than those of control group(P<0.05).The incidence of gastrointestinal reaction,loss of appetite,leukopenia and decreased hemoglobin in observation group were lower than those in control group(P<0.05).The improvement rate of life quality in observation group(56.60%)was higher than that in control group(30.19%)(P<0.05).The levels of serum CEA,VEGF,CA19-9,NSE,Treg cells,Th17 cells,Treg/Th17,PD-1 and PD-L1 in two groups after 1 and 3 cycles of treatment were lower than before treatment(P<0.05),and those in the observation group was lower than in the control group(P<0.05).The 1-year survival rate of two groups had no statistical difference(P>0.05).Conclusion Ginseng polysaccharide injection combined with sindillizumab in the treatment of advanced NSCLC patients with chemotherapy can enhance immunity,enhance efficacy and reduce toxicity,and improve the quality of life of patients.
作者
袁航
魏娜
任统伟
YUAN Hang;WEI Na;REN Tongwei(Department of Oncology,Zhang Zhongjing Hospital,Nanyang 473000,China)
出处
《河南医学研究》
CAS
2023年第18期3349-3352,共4页
Henan Medical Research
基金
河南省中医药科学研究专项课题(20-21ZY3032)。
关键词
非小细胞肺癌
信迪利单抗
人参多糖注射液
non-small cell lung cancer
sindilimab
ginseng polysaccharide injection
